Xaluritamig
- Generic Name
- Xaluritamig
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT06613100
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 40
- Registration Number
- NCT06555796
- Locations
- 🇦🇺
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
🇦🇺Cabrini Hospital, Malvern, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath